Literature DB >> 8603642

Long-term otucome of West syndrome: a study of adults with a history of infantile spasms.

R Riikonen1.   

Abstract

To our knowledge, ours is the first study to evaluate the outcome of infantile spasms (IS) in adult patients. We analyzed 214 children born between 1960 and 1976 who had been followed for 20-35 years or until death at 3 months to 30 years of age. Mortality was 31% (67 of 214 patients). Thirty-six of the surviving patients (24%) had normal (25 patients) or only slightly impaired (11 patients) intelligence as assessed by their educational abilities. Four had academic occupations. Eight were married or living unmarried with a partner. Five had healthy children. At follow-up, the EEGs of the 25 normal persons were either normal or slightly abnormal, demonstrated focal findings in 9 (36%), and had unspecific changes in 1. Focal abnormalities were not more common in patients with less good outcomes (37%). In patients with normal neurological outcomes, IS had been classified as cryptogenic only in 9 of 25 (36%) cases. Therefore, some patients with IS apparently have normal intelligence and socioeconomic status as adults, including patients whose spasms were either symptomatic or associated with focal EEG findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603642     DOI: 10.1111/j.1528-1157.1996.tb00573.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  16 in total

Review 1.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

2.  Diagnosis delay in West syndrome: misdiagnosis and consequences.

Authors:  Stéphane Auvin; Adam L Hartman; Béatrice Desnous; Anne-Christine Moreau; Corinne Alberti; Catherine Delanoe; Alfonso Romano; Gaetano Terrone; Eric H Kossoff; Ennio Del Giudice; Luigi Titomanlio
Journal:  Eur J Pediatr       Date:  2012-08-15       Impact factor: 3.183

Review 3.  Novel animal models of pediatric epilepsy.

Authors:  Stéphane Auvin; Eduardo Pineda; Don Shin; Pierre Gressens; Andrey Mazarati
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 4.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

Review 5.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

6.  Neurodevelopmental outcomes in children with Down syndrome and infantile spasms.

Authors:  Sarah Tapp; Tovi Anderson; Jeannie Visootsak
Journal:  J Pediatr Neurol       Date:  2015-06

7.  West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence?

Authors:  Salvatore Mangano; Rosaria Nardello; Gabriele Tripi; Giuliana Giordano; Chiara Spitaleri; Giuseppa Renata Mangano; Antonina Fontana
Journal:  BMC Neurol       Date:  2013-05-24       Impact factor: 2.474

8.  Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort.

Authors:  Zachary M Grinspan; Kelly G Knupp; Anup D Patel; Elissa G Yozawitz; Courtney J Wusthoff; Elaine Wirrell; Ignacio Valencia; Nilika S Singhal; Douglas R Nordli; John R Mytinger; Wendy Mitchell; Cynthia G Keator; Tobias Loddenkemper; Shaun A Hussain; Chellamani Harini; William D Gaillard; Ivan S Fernandez; Jason Coryell; Catherine J Chu; Anne T Berg; Renee A Shellhaas
Journal:  Neurology       Date:  2021-07-15       Impact factor: 11.800

9.  Current trends in the treatment of infantile spasms.

Authors:  Chang-Yong Tsao
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

10.  An effective initial polytherapy for children with West syndrome.

Authors:  Feiyong Jia; Huiyi Jiang; Lin Du; Ning Li; Ji Sun; Chunbo Niu
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.